A user confirmed that koshinemall.com is the official site for buying Pyrilutamide after contacting Kintor directly. They expressed initial skepticism due to the website's quality and phone number requirement.
A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
The user is experimenting with a zinc sulfate and B6 topical solution called "Zix" for hair loss, alongside using a zinc oxide scalp mask and low-level laser therapy (LLLT). They report minimal hair loss after three months of use and are seeking feedback from others who have tried similar treatments.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.
AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.
The conversation discusses using ZIX, a combination of Zinc Sulfate and Vitamin B6, for hair loss. The user is considering liquid forms for better absorption and scalp health.
Copper peptides are discussed as a potential alternative to minoxidil for treating hair loss. Users share interest and challenges in accessing copper peptides, with some mentioning specific products.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
A 30-year-old man with hairline recession is considering using 1% Clascoterone cream on his hairline while awaiting a 5% Breezula product. He has been using oral Minoxidil for four years but stopped using Finasteride due to side effects.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.
Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.
The conversation is about managing an itchy, flaky scalp, possibly due to psoriasis, and the use of a hydrating conditioner to address dryness. The user is concerned about using conditioner due to experiencing telogen effluvium.
A 26-year-old male is using a combination of clomiphene, minoxidil, tadalafil, bupropion, and lisdexamfetamine to address low testosterone, ED, depression, and focus issues. He seeks input on the safety and efficacy of this regimen, which also includes magnesium, zinc, and fish oil supplements.
A user experienced severe side effects from using topical minoxidil sublingually, including muscle cramps, dizziness, and high potassium levels. They were advised to stop and seek medical help, emphasizing that topical minoxidil is not safe for ingestion due to its alcohol content.
Iron and zinc vitamins helped improve hairline regrowth for someone with celiac disease. Nutrient deficiencies, like iron, can contribute to hair loss, especially around the temples.
Clascoterone lotion, being tested in Germany, is as effective as Minoxidil and Finasteride for hair loss but without serious side effects. About 400 men participated in the trials.
FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
The conversation discusses the lack of clinical studies on cysteine alone for hair loss, with the original poster already using medications like Minoxidil and finasteride. Suggestions include trying 2ddr as a growth stimulant, though concerns about side effects like gas are mentioned.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.
RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.